GoodRx Holdings, Inc. (GDRX) Q1 2024 Earnings Call Transcript
GoodRx Holdings, Inc. (GDRX) Q1 2024 Earnings Call Transcript
GoodRx | 10-Q: Quarterly report
Change Healthcare Cyberattack: GoodRx Expects Low Single Digit Million-Dollar Impact In 2024
Thursday, GoodRx Holdings (NASDAQ:GDRX) reported a first-quarter adjusted EPS of $0.08, which was in line with the consensus and higher than the $0.07 reported a year ago.The company reported sales of
Research Alert: CFRA Maintains Buy Opinion On Shares Of Goodrx Holdings, Inc.
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We trim our 12-month target price by $1
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX), Petiq (PETQ) and Biodesix (BDSX)
GoodRx Holdings (NASDAQ:GDRX) Could Be Struggling To Allocate Capital
GoodRx Forecasts 2024 Revenue Of $800M-$810M Versus Consensus Of $857.80M, With Adjusted EBITDA Over $250M
GoodRx Forecasts 2024 Revenue Of $800M-$810M Versus Consensus Of $857.80M, With Adjusted EBITDA Over $250M
GoodRx Holdings' Q1 Adjusted Earnings, Revenue Rise
GoodRx Holdings (GDRX) reported Q1 adjusted earnings Thursday of $0.08 per diluted share, up from $0.07 a year earlier. Analysts polled by Capital IQ expected $0.08. Revenue for the quarter ended Marc
GoodRx Forecasts Q2 Revenue Of ~$200M Versus Consensus Of $199.57M, With Adjusted EBITDA Margin In Low Thirty-Percent Range
GoodRx Forecasts Q2 Revenue Of ~$200M Versus Consensus Of $199.57M, With Adjusted EBITDA Margin In Low Thirty-Percent Range
GoodRx Holdings (GDRX.US): The 2024 Q1 financial report achieved revenue of US$197.9 million, with a previous value of US$184 million, with an expected value of US$196 million; earnings per share were US$0.08, previous value was US$0.07, and expected valu
GoodRx Holdings (GDRX.US): The 2024 Q1 financial report achieved revenue of US$197.9 million, with a previous value of US$184 million, with an expected value of US$196 million; earnings per share were US$0.08, previous value was US$0.07, and expected value was US$0.07.
Earnings Flash (GDRX) GOODRX HOLDINGS Reports Q1 Adjusted EPS $0.08
06:12 AM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (GDRX) GOODRX HOLDINGS Reports Q1 Adjusted EPS $0.08
GoodRx Holdings Shares Are Trading Lower Following Q1 Earnings.
GoodRx Holdings Shares Are Trading Lower Following Q1 Earnings.
GoodRx Holdings Beats Top-line and Bottom-line Estimates; Initiates Q2 and Updates FY24 Outlook
GoodRx Holdings Q1 2024 Adj. EPS $0.08, Inline, Sales $197.880M Beat $196.082M Estimate
GoodRx Holdings Q1 2024 Adj. EPS $0.08, Inline, Sales $197.880M Beat $196.082M Estimate
GoodRx Holdings 1Q Loss $1.01M >GDRX
GoodRx Holdings 1Q Loss $1.01M >GDRX
GoodRx Holdings 1Q Rev $197.9M >GDRX
GoodRx Holdings 1Q Rev $197.9M >GDRX
Press Release: GoodRx Reports First Quarter 2024 Results
GoodRx Reports First Quarter 2024 Results SANTA MONICA, Calif.--(BUSINESS WIRE)--May 09, 2024-- GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading dest
Investor Optimism Abounds GoodRx Holdings, Inc. (NASDAQ:GDRX) But Growth Is Lacking
GoodRx Holdings, Inc.'s (NASDAQ:GDRX) price-to-sales (or "P/S") ratio of 3.2x may not look like an appealing investment opportunity when you consider close to half the companies in the Healthcare Serv
Analysts Are Bullish on These Healthcare Stocks: GoodRx Holdings (GDRX), Arcutis Biotherapeutics (ARQT)
Press Release: GoodRx Announces Date for First Quarter 2024 Earnings Release and Conference Call
GoodRx Announces Date for First Quarter 2024 Earnings Release and Conference Call SANTA MONICA, Calif.--(BUSINESS WIRE)--April 11, 2024-- GoodRx Holdings, Inc. (Nasdaq: GDRX) ("GoodRx" or the "Compa
No Data